遗传异质性急变期慢性髓性白血病的通路汇聚整合模型
该研究对74例慢性期和急变期慢性髓性白血病样本进行多组学整合分析,发现急变期基因组显著富集多梳抑制复合物(PRC)通路相关突变,PRC2驱动DNA高甲基化沉默髓系分化与抑癌基因,PRC1抑制另一组包括新抑癌基因在内的基因,据此建立急变期整合模型并识别可逆转重编程的联合疗法。
要点
- 急变期基因组显著富集PRC通路突变,转录组呈现PRC1相关基因集富集而PRC2相关基因集耗竭。
- PRC2驱动DNA高甲基化经表观遗传切换沉默髓系分化和抑癌基因,PRC1抑制重叠且不同的基因集。
- 整合模型识别出地西他滨联合PRC1抑制剂可逆转急变期重编程,并发现NR4A2等新抑癌基因。
核心结论
- 急变期慢性髓性白血病 progenitor 经历PRC驱动的表观遗传重编程,趋向汇聚的转录组状态。
研究设计与样本
- 对74例慢性期和急变期慢性髓性白血病样本进行全基因组和全外显子测序、转录组和甲基化组分析及染色质免疫沉淀高通量测序的多组学整合分析。
主要发现
- 急变期基因组显著富集影响多梳抑制复合物(PRC)通路组分的突变。
- 急变期 progenitor 转录组中PRC1相关基因集富集而PRC2相关基因集耗竭。
- PRC2驱动急变期DNA高甲基化,经表观遗传切换沉默髓系分化和抑癌功能关键基因。
- PRC1抑制一组重叠且不同的基因,包括新急变期抑癌基因。
关键数值与推荐
- 急变期基因组显著富集PRC通路突变。
- 急变期 progenitor 中PRC1相关基因集富集、PRC2相关基因集耗竭。
- PRC2驱动DNA高甲基化沉默关键基因,PRC1抑制重叠且不同基因集。
临床怎么用
- 整合模型有助于识别能逆转急变期重编程的联合疗法(地西他滨+PRC1抑制剂)。
- 模型促进发现新的PRC沉默抑癌基因(NR4A2)及预测慢性期疾病进展和耐药的基因表达特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted therapies against the BCR-ABL1 kinase have revolutionized treatment of chronic phase (CP) chronic myeloid leukemia (CML). In contrast, management of blast crisis (BC) CML remains challenging because BC cells acquire complex molecular alterations that confer stemness features to progenitor populations and resistance to BCR-ABL1 tyrosine kinase inhibitors. Comprehensive models of BC transformation have proved elusive because of the rarity and genetic heterogeneity of BC, but are important for developing biomarkers predicting BC progression and effective therapies. To better understand BC, we performed an integrated multiomics analysis of 74 CP and BC samples using whole-genome and exome sequencing, transcriptome and methylome profiling, and chromatin immunoprecipitation followed by high-throughput sequencing. Employing pathway-based analysis, we found the BC genome was significantly enriched for mutations affecting components of the polycomb repressive complex (PRC) pathway. While transcriptomically, BC progenitors were enriched and depleted for PRC1- and PRC2-related gene sets respectively. By integrating our data sets, we determined that BC progenitors undergo PRC-driven epigenetic reprogramming toward a convergent transcriptomic state. Specifically, PRC2 directs BC DNA hypermethylation, which in turn silences key genes involved in myeloid differentiation and tumor suppressor function via so-called epigenetic switching, whereas PRC1 represses an overlapping and distinct set of genes, including novel BC tumor suppressors. On the basis of these observations, we developed an integrated model of BC that facilitated the identification of combinatorial therapies capable of reversing BC reprogramming (decitabine+PRC1 inhibitors), novel PRC-silenced tumor suppressor genes (NR4A2), and gene expression signatures predictive of disease progression and drug resistance in CP.
引用
- Ko TK, Javed A, Lee KL, et al. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood. 2020. PMID: 32157296. doi:10.1182/blood.2020004834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。